Skip to main content
Journal of Lipid Research logoLink to Journal of Lipid Research
. 2016 Oct 27;57(11):1987–1994. doi: 10.1194/jlr.R071712

A short history of inositol lipids

Robin F Irvine 1,1
PMCID: PMC5087877  PMID: 27623846

Abstract

The diverse family of inositol lipids is now known to be central to many aspects of cell biology. The route from the first discovery of inositol to our present day knowledge of inositol lipids spans more than 150 years and is long and complex. This is a brief account of some of the most important stages along that route.

Keywords: phosphoinositides, phospholipases/C, phospholipids, phospholipids/phosphatidylinositol, receptors/hormone, history, phosphatidylinositol, polyphosphoinositol lipids


This is an enormous topic, were full justice to be done to it, because inositol lipids (and their derivatives/cousins, the inositol phosphates) impinge on a substantial proportion of cell biology. But this account will be short and informal, and in places personal. In the latter context, I have been fortunate enough to meet most of the pioneers mentioned below in person, and some of the tales and apocryphal stories come from discussions with them, often related to me after several beers. For those interested in further reading, Bob Michell has written a very full account of the history of inositol lipid signaling (1), and personal recollections from him (2), Clint Ballou (3), Michael Berridge (4), and Lowell Hokin (5) have also been published. As if that were not enough, I have recently published a personal account of the halcyon days of inositol trisphosphate (IP3) (6).

So perhaps we have enough history in total, and I see my task here being to write a story that is complete insofar as I don’t knowingly miss out on anything really crucial, but short enough to be digestible and entertaining. So this is not a complete history, but a succinct one, and I know that I will leave out many important papers and individuals; I hope no one is offended.

EARLY FOUNDATIONS

Inositol (myo-inositol, see below) was first isolated by Scherer (7), and called “inosite” because of its sweet taste. It was fully purified by Maquenne in 1887 (810) and its inert (compared with glucose) chemical behavior, the molecular weight of its acetyl and benzoyl esters, and other chemical properties led him to establish its cyclohexanol structure by a beautiful series of classic papers; do read them if you can. Maquenne first isolated inositol from leaves, but later used large quantities of horse urine reduced by boiling, which apparently led to complaints from his neighbors. There are nine different possible isomers of inositol, and it was largely the elegant work of Posternak that established the configuration of the principle inositol in eukaryotic tissues, myo-inositol [(11, 12) and see (13) for review]. Posternak was also responsible for the identification of phytic acid, the major store of organic phosphate in seeds, as being myo-inositol hexakisphosphate in the first decade of the 20th century (14).

Before continuing the main thread of this story, it is worth noting as an aside that other inositols (e.g., scyllo, epi, and neo) occur in nature and isomerases that interconvert some of them (whose functions are as yet unknown) may be present in eukaryotes (15). In the soil, inositol hexakisphosphates are found based on isomers other than myo-inositol (1618), and some eukaryotes, such as Entamoeba histolytica, make neo-inositol hexakisphosphate (19). It could be that there is an entire biochemistry out there of other inositols in other organisms of which we are currently almost completely ignorant.

PHOSPHATIDYLINOSITOL

The esterified existence of inositol in lipids (which from now on will be only the myo isomer) first emerged from bacteria (20), some of which (e.g., the tuberculosis pathogen) have complex inositol lipids [see (3)]. Later, esterified inositol was established as a component of eukaryotic lipids in plants (21) and mammals (22, 23). The pioneering chemistry of Clint Ballou and his coworkers led to the demonstration of phosphatidylinositol (PI) having the diester phosphate link between the 3-carbon of glycerol (in sn nomenclature) and the D-1-hydroxyl of the inositol (24). In the modern context of signaling, Ballou’s contributions to the structures of polyphosphoinositol lipids (discussed below) are the best known, but the extensive body of earlier work that included de novo synthesis of new enantiomers to establish PI’s structure (25) was an equally important and elegant piece of work. Parallel work by Dan Brown and his colleagues (26) made an additional crucial contribution to the establishment of PI structure.

ISOMERS AND NOMENCLATURE

This is a good point at which to refresh the reader’s memory on numbering and enantiomers. Anyone who has heard me lecture on inositides will be aware of my fondness for Bernie Agranoff’s turtle analogy (27) to clarify what can be a confusing issue. Figure 1 [adapted from (28)] illustrates this, and can be used by any isomerically challenged reader. The anti-clockwise numbering of the turtle who (like most of us) is right-flippered so his front right flipper is number 1, is then easy to remember. Note the axis of symmetry running through the turtle’s head to his tail, so inositol 1 and 3 phosphate, and inositol 4 and 6 phosphate, are enantiomeric pairs and inositol 2 and 5 phosphate are meso compounds.

Fig. 1.

Fig. 1.

Myo-inositol displayed as a Howarth projection (A), a more stereochemically correct depiction (B), and as Agranoff’s turtle (C). Taken from (28).

Because this review is historical and might induce a reader to look at original papers from the past, it is important to remember that, around the 1970s, the official designation of what is D and what is L in inositol numbering was swapped over (to get L-numbering, start with the turtle’s front left flipper as 1 and number clockwise). Thus, for example, Clinton Ballou’s work (24) on inositol lipid structure established the phosphodiester link between glycerol and inositol as involving what they called the L-1 position of inositol, though it is what we now know as the D-1 position (the front right flipper on the turtle). A similar potential confusion can arise from reading Frank Eisenberg’s (29) classic designation of the two isomers of inositol monophosphate that arise from biosynthesis from glucose-6-phosphate versus alkaline hydrolysis of PI. These are an enantiomeric pair, in modern nomenclature D-inositol 3-phosphate and D-inositol 1-phosphate, respectively, but in the relevant paper (29), they are designated the other way around.

Finally, it is a rule of chemistry that the lowest isomeric numbering should be used if possible, so D-inositol 3-phosphate should more properly be called L-inositol 1-phosphate. This rule was relaxed in the 1990s to make the biochemistry of inositol phosphate metabolic pathways easier to follow, and throughout the rest of this review I will use modern rules and designations without further qualification or discussion.

PI4P AND PI(4,5)P2

In the 1940s, Jordi Folch-Pi published a series of fractionations of bovine brain (30) that ultimately led to a fraction that was (as we know now) an approximately equal mixture of PI, PI4P [PI phosphate (PIP) (the number denotes the isomeric position of monoester phosphate)], and PI(4,5)P2 [PI bisphosphate (PIP2) (the parenthesized numbers denote the isomeric positions of monoester phosphates)] with a little PE (31); it is remarkable just how “pure” this mixture is, given that it has no chromatography in its protocol, only precipitations. Because the ratio of phosphorus to inositol ends up as about 2, Folch-Pi called it “diphosphoinositide” (31). It remained as such until the early 1960s, when two groups took it a stage further. Rex Dawson’s group purified PI(4,5P)2 and, from its phosphate/inositol ratio of 3:1, called it “triphosphoinositide” (TPI) (32). Concurrently, Clinton Ballou’s group hydrolyzed Folch-Pi’s diphosphoinositide with alkali and identified a variety of inositol phosphates that led them to conclude that PI plus a PI4P and a PI(4,5)P2 were present (33, 34). Later, Brown and Stewart (35) submitted a large quantity of triphosphoinositide (given to them by Dawson) to a similar analysis to confirm that Dawson’s purified “TPI” was indeed Ballou’s deduced PI(4,5)P2.

Close reading of one of the works from Ballou’s laboratory (33) reveals a very warm acknowledgment to a Stephen Freer for “dedicated technical assistance.” This has a story behind it, in that isolating the many grams of Folch-Pi fraction that they worked with from more than 100 cow brains necessitated gallons of flammable chemicals, so the early stages were conducted on the roof of the chemistry department in Berkley. Apparently, as one preparation neared its late stages it caught fire and Mr. Freer risked his life to save it, probably not least because of the horrendous thought of months of hard work with cow brains and solvents going up in smoke!

PI4P and PI(4,5P)2 are found at much higher levels in animal tissues than the other five polyphosphoinositol lipids, and this, plus their presence in the plasma membrane and thus at very high levels in myelin, led to their discovery nearly 30 years before the others; I will deal with the others at a later stage.

PI(4,5)P2 FUNCTION: THE PLC STORY

Actually, it is functions in the plural we are talking about, as we now know PI(4,5)P2 to be one of the most multi-functional molecules in biology (36). But from a historical viewpoint, the whole story of inositol lipid function focused on, and was inextricably linked to, its role as a generator of two second messengers, diacylglycerol (DAG) and inositol 1,4,5-trisphosphate, by virtue of its being split in half by members of the phosphoinositide-specific phospholipase C (PI-PLC) family (Fig. 2).

Fig. 2.

Fig. 2.

Basic scheme of the PIP2-PLC cycle. Taken from (98).

In the early 1950s, Lowell and Mabel Hokin were working in Sheffield investigating the control of RNA synthesis by incorporation of 32P, and discovered a clear increase when pancreatic slices were stimulated with acetylcholine. They were due to move to Canada (McGill University), so they packed up the radioactive material and took it with them over the Atlantic (imagine doing that in the 21st century…) and proceeded to purify the RNA from the extracts. As they purified it, the radioactivity disappeared, so they analyzed the radioactive “junk” they had discarded and found that it was phospholipid. They published this seminal observation in 1953 (37). As Mabel later recalled, at this stage they could go no further because simple ways of separating and analyzing phospholipids from small quantities of tissue did not then exist. But the following year, Rex Dawson published his classic analytical method based on alkaline deacylation and two-dimensional separation of the glycerophosphoesters (38). A further observation he made, not usually noted by historians (because most people do not read the paper), was that if slices of tissue (brain or pancreas) were acutely labeled with 32P, the majority of radioactivity was in phosphatidic acid (PA) and inositides, especially the diphosphoinositide fraction (38). The Hokins seized on this method and confirmed Dawson’s observations for their actetylcholine-stimulated pancreatic slices: the increase in labeling they observed was almost all in PA and PI (39). The “phosphoinositide effect” was born.

The long and complex story of how this phenomenon was studied and discussed at length for the next 30 years is too much for relating here; Bob Michell has written an excellent account of these events (1, 2). There is an interesting theme that emerges from these studies, which illustrates the general principle of how you measure things can dictate what you see. For many years, the stimulated incorporation of 32P into PA and PI was the easiest and, therefore, most widely used method, but this is of course indirect, and its sensitivity stems from the fact that the DAG generated by PI-PLC is phosphorylated into PA by DAG kinase, which is then incorporated directly [after activation to CMP-PA, also known as CDP-DAG (40)], so if the tissue is not labeled to equilibrium, this radiolabel incorporation exaggerates the actual mass rate of synthesis. Thus, even if there were a stimulation of a PC-specific PLC, because the phosphocholine and CDP-choline pools would still be at a lower specific activity than the γ phosphate of ATP, the most prominent effect with acute 32P labeling could still be a specific increase in PA and PI labeling. Quantifying PI breakdown was challenging (41, 42), not least because under most circumstances when PI-PLC is activated there is no detectable drop in PI mass levels (the amount of PI consumed to replenish PIP2 levels is quite small); indeed, even PIP2 often does not go down detectably due to rapid compensatory resynthesis (see, e.g., (43) for an early report of this).

So the indirect method of measuring the “PI effect” was used almost exclusively and this unsurprisingly led to some false directions. Nevertheless, the discovery of a specific PI-PLC (44, 45) and the PI decreases (41, 42) led to the general consensus that a hydrolysis of inositol lipids was the likely primary reaction (46, 47). The PI-PLC family is now known to be a large one, with complex regulations by cell surface receptors as well as intracellular factors such as monomeric G-proteins. Many laboratories contributed to that story, but most people would agree that Sue-Goo Rhee’s extensive set of studies [see (48) for review] was the major clarifying factor.

With the benefit of hindsight, the earliest guess nearest to correctness as to inositol lipid function in the 1960s came from Jack Durell and his coworkers, who suggested that TPI hydrolysis was connected to acetylcholine receptor activation, though they proposed that nicotinic (rather than muscarinic) receptors were responsible (49). The real breakthrough and cohesive synthesis of inositide function came with Bob Michell’s (47) seminal suggestion that PI-PLC activation was a part of the signaling function of a group of receptors distinct from those coupled to adenylyl cyclase. Moreover, he crucially suggested that increases in calcium influx were a part of the response to PI turnover (47).

For a while, there was a lot of argument as to which out of calcium rises and PI turnover was the chicken or the egg. Here again, the method of measurement could cause confusion. For example, for a number of years arguments raged about whether the neutrophil, in which the increase in PA labeling was clearly dependent on extracellular calcium being present (50), was a “black swan,” which disproved the hypotheses that all swans were white (i.e., if PI turnover preceded calcium in the pathway, it should always be calcium-independent). But Shamshad Cockcroft (50) eventually showed that the PA being quantified was at a lower specific activity than the PI, and indeed had a different fatty acid profile (51). In fact, a large (extracellular calcium-dependent) increased activation of phospholipase D activity on PC was confusing the whole issue, and so the neutrophil was actually a rather dirty swan. The clearest experimental link between calcium homeostasis and the PI effect came from the classic demonstration by Berridge and Fain (52) that blowfly salivary glands depended on a supply of inositol to support sustained calcium rises.

Arguments about calcium dependency also muddied the waters for a time as to whether PI or PIP2 was the primary substrate of PI-PLC in vivo [see e.g., (53)]. Not least of the arguments against PIP2 was the question, why do cells have so much PLC activity against PI if PIP2 is the major substrate in the cell? This was answered by the demonstration that the various PI-PLCs could hydrolyze both substrates (54) and that they favor PIP2 under physiological assay conditions (55, 56), which suggested that Dawson’s TPI-phosphodiesterase (57) and PI-phosphodiesterase (44, 45) were probably the same beast.

While on the subject of TPI-phophodiesterase, this is a good place to mention that when it was discovered Dawson and Thompson (58) also described a phosphatase with different properties from the phosphodiesterase (e.g., not calcium-dependent, but requiring magnesium), which removed the monoester phosphate from PIP2 to generate PIP. This was the very beginning of the polyphosphoinositol lipid phosphatase story. This family of enzymes has grown enormously in the intervening years, and is now recognized as having major physiological and pathological significance [see (59) for a recent review].

The final resolution of the PI/PIP2 argument came about when the products of hydrolysis were analyzed after [3H]inositol labeling of tissues. In particular, Mike Berridge’s demonstration that IP3 was clearly the product formed first (within seconds) after blowfly salivary glands were stimulated (60) was crucial, and he later showed with some elegant stop-flow and electrophysiological experiments that this increase preceded any physiologically significant detectable rise in calcium (61). The proposal (60) that IP3 might therefore be the mediator of the calcium rises was followed by the experimental demonstration that this was so by Streb et al. (62) in the same year.

As mentioned above, Mike Berridge (4) and I (6) have both written personal accounts of the events that led to the publication of Streb et al. (62), so I will not add to the length of this review by reiterating any of that. I also describe (6) how the concurrent discovery of 134IP3 started the proliferation of inositol phosphates, with their many functions [e.g., (6365)]. Inositol phosphates are not lipids by any stretch of the imagination, so their story does not belong here, but it is important to remember that in most eukaryotes (plants and slime molds being the most notable exceptions) the only route to the inositol phosphate family goes via the generation of 1,4,5-trisphosphate by PI-PLC, and not by phosphorylation all the way up from inositol; thus, the first three phosphorylations of the inositol ring take place in the lipids. So even in organisms such as yeast where IP3 has no known function itself, it is the essential precursor of all the other IPs (66).

The other product of PI-PLC is DAG, and that is indeed a lipid and is a centrally important second messenger. Nishizuka and colleagues’ seminal discovery of PKC as a DAG-activated protein kinase happened in 1979 (67), before IP3 was in any way suspected of having a function, drew many people into taking an interest in inositol lipids. This discovery was a typical example of impure compounds aiding advances; when Nishizuka’s group switched over to an alternative commercial source of phosphatidylserine (required by PKC) that was pure, and was not contaminated by DAG, the massive decrease in PKC activity led them to identify the missing stimulant. The double precursor role of PIP2 as a generator of two synergizing second messengers is a truly remarkable aspect of cell physiology. PI(4,5)P2 is now known to have many other functions in its own right [see (36) for a comprehensive and magisterial review of this topic].

THE “OTHER” POLYPHOSPHOINOSITOL LIPIDS

PI4P, for a long time thought to be “just” a precursor to PI(4,5)P2, is now recognized as having many physiological functions, in particular in intracellular membranes such as the Golgi [reviewed by Balla (36)], though it may also have a distinct crucial function in contributing to the high negative charge of the plasma membrane (68).

The remaining five polyphosphoinositol lipids (Fig. 3) are present in eukaryotic cells at one to two orders of magnitude lower than the levels of PI4P and PI(4,5)P2, so they eluded discovery for a long time. The advent of HPLC analysis of deacylated [3H]inositol-labeled lipids was the major spur for discovery and analysis of these physiologically crucial cell components. The origins of the 3-phosphorylated family stem back to the discovery of what was thought to be a PI 4-kinase activity associated with oncogenes src and middle T antigen (69, 70). This activity was originally thought to be perhaps boosting PI4P levels to amplify the PI-PLC signals, but the continuation of this story by Cantley’s group showed that the oncogene-associated activity was molecularly distinct from the other PI kinases, and that it was differentially regulated by tyrosine kinases (71). Finally, they showed that their kinase was a PI 3-kinase (72). PI34P2 and PIP3 emerged as products produced in vitro by this activity if given the appropriate substrate (73), although PIP3 was first reported in intact cells as a rapidly-produced lipid in stimulated neutrophils (74).

Fig. 3.

Fig. 3.

The polyphosphoinositol lipids. Adapted from (99). PI (A) and a schematic depiction of PI and the seven polyphosphoinositol lipids (B).

For a while there was considerable confusion, not unlike that earlier for PLC, as to which of the three 3-phosphorylated inositol lipids was produced first in vivo and thus which might be the primary functional molecule. This confusion was not helped by the identification by Waterfield and Emr’s groups of PI 3-kinase as a homolog of the yeast vps34 protein, which would only use PI as a substrate to generate PI3P (75) and would not phosphorylate PIP2.

The clarification of PIP3 as a molecule generated directly by 3-phosphorylation of PI(4,5)P2 by a receptor-stimulated enzyme (thus echoing the generation of IP3) came largely from Len Stephens and Phill Hawkins and their colleagues. They showed first, that we mammals have a PI-specific 3-kinase similar to yeast, but distinct from the enzyme(s) (there are four in vertebrates) that specifically phosphorylate PI(4,5)P2, so PI3P is a separate story from PIP3 (76). More importantly, elegant analysis of the individual phosphate moieties on the inositol ring under nonequilibrium labeling conditions established the receptor-stimulated activity in vivo as being 3-phosphorylation of PI(4,5)P2 (77, 78). PIP3 has proved to be a second messenger of immense physiological significance, with numerous effectors (the two inter-twined protein kinases, Akt and PDK, being the most famous), and I do not propose to tell that complex story here: Alex Toker (79) has written an excellent historical account of the phosphoinositide 3-kinases.

PI3P is now appreciated as a crucial part of cellular trafficking, and PI(3,4)P2 is finally coming into its own limelight as a messenger in its own right [see (36)]. It is interesting to note in this historical context that PI3P may have been the first polyphosphoinositol lipid to appear during evolution. We eukaryotes make PI by combining inositol with activated PA (CMP-PA, also known as CDP-DAG) (40), but some bacteria, such as Mycobacterium, apparently use inositol 3-phosphate (synthesized from glucose 6-phosphate) instead to make PI3P, which is then dephosphorylated to PI (80). Archaea do something similar, though their lipids are based on backbones different from the 1,2,DAG [see (81) for review]. Whether PI3P has a function in these organisms, other than as a synthetic precursor to PI, is not known.

PI(3,5)P2 was discovered independently by Charles Brearley and his colleagues (82) and by the combined groups of Peter Parker and Bob Michell (83), who identified it on HPLC profiles as a peak greatly enhanced by osmotic stress in yeast; this lipid is again also now appreciated as a major player in cell trafficking regulation (36).

Finally, Lucia Rameh in Lew Cantley’s group was investigating the specificity of a PI(4,5)P2 5-phosphatase, specificity being, in this context, how often it removed the 4-phosphate instead of the 5-phosphate. She quantified this side reaction (about 5% of the total activity) by the production of labeled PI5P from 32P-5-labeled PIP2, which had been prepared by incubating PI4P with a recombinant PI4P 5-kinase and 32P-ATP. Lucia ran out of recombinant PIP kinase, and used some enzyme purified from red cells that was in the laboratory deep freeze in its place, and was astonished to see a massive generation of radiolabeled PIP by the phosphatase. The reason, elegantly teased out, was that the PI4P (from brain) was contaminated with some PI5P, and that the red cell enzyme, a type II PIP kinase, is actually a PI5 4-kinase, not a PI4P 5-kinase (84). So this batch of 32PI(4,5)P2 was instead labeled in the 4-position, and consequently the predominant 5-phosphatse activity of the enzyme being studied now generated copious quantities of radiolabeled PIP! The identification in animal tissues of the natural substrate of type II PIP kinases (now known as PI5P4Ks), PI5P, followed (84), and this lipid is now also established as having multiple effectors in the cytoplasm and nucleus [see (8587) for reviews].

Mention of the nucleus prompts the aside that nuclear inositol lipid metabolism and function, first established in the late 80s/early 90s (88, 89) is a growing aspect of the inositol lipid field (see, e.g., (90) for review) and reflects yet again the diversity and ubiquity of these minor, but crucially important, lipids.

PI-GLYCAN ANCHORS

Finally, these should be included here as another remarkable diversification of inositol lipid chemistry and function. It was known by the 1970s that some snake venoms and bacterial extracts could cause release of enzymes into the bloodstream [see, e.g., (91) for early references] and it was Martin Low and his colleagues who showed that a bacterial PI-specific PLC liberated these proteins because they were bound to the outside surface of cells by a covalent link to an inositol lipid (9193). The full structure of the complex inositol lipid (the 6-hydroxyl of the inositol ring is employed here) was worked out by Mike Ferguson and his colleagues [e.g., (94) and see (95) for a review of the complex chemistry of PI-glycans in parasitic protozoa]. In addition to being a releasable way of attaching proteins to the outside of our cells (of particular significance in immune cells), this link is employed by the parasites to rapidly shed their coat proteins and thus avoid immune surveillance.

CONCLUSION

When we look at just how many inositides there are, doing how many amazing things, it is not surprising that the emergence of our current knowledge was a complex path with many false leads and took decades. As with any such tale, it is much easier told with the benefit of hindsight, but if there is one lesson for us all, it is that almost all of the discoveries described above were made from what we would now call “blue-skies” research, with no clear aim or practical endpoint other than the uncovering of knowledge. How many of the studies described above would be funded now? No matter how many times we tell those who try to direct science that much of it cannot be directed, they don’t seem to listen.

Acknowledgments

The author thanks all those inositide pioneers whom he has met over 40 years for insights into how some of these events happened, and especially Bob Michell for his unmatched historical knowledge. The author’s involvement with inositol lipids and phosphates began when, as an undergraduate, he read a review by Rex Dawson (96), which led to the author joining his lab (97). The author is acutely conscious of the debt that he and the whole field owe Rex Dawson.

Footnotes

Abbreviations:

DAG
diacylglycerol
PA
phosphatidic acid
PI
phosphatidylinositol
PIP
phosphatidylinositol phosphate
PIxP
phosphatidylinositol phosphate (x denotes the isomeric position of monoester phosphate)
PIP2
phosphatidylinositol bisphosphate
PI(x,y)P2
phosphatidylinositol bisphosphate (x,y denote the isomeric positions of monoester phosphates)
PI-PLC
phosphoinositide-specific phospholipase C
PLC
phospholipase C

REFERENCES

  • 1.Michell R. H. 1986. Inositol lipids and their role in receptor function: history and general principles. In Phosphoinositides and Receptor Mechanisms. J. W. Putney, Jr., editor. Alan Liss, New York. 1–24. [Google Scholar]
  • 2.Michell B. 1995. Early steps along the way to inositol-lipid-based signalling. Trends Biochem. Sci. 20: 326–329. [DOI] [PubMed] [Google Scholar]
  • 3.Ballou C. E. 2004. My brief encounter with the phosphoinositides and IP3. J. Biol. Chem. 279: 54975–54982. [DOI] [PubMed] [Google Scholar]
  • 4.Berridge M. J. 2012. Discovery of the second messenger inositol trisphosphate. Messenger (Los Angel.). 1: 3–15. [Google Scholar]
  • 5.Hokin L. E. 1987. The road to the phosphoinositide-generated second messengers. Trends Pharmacol. Sci. 8: 53–56. [Google Scholar]
  • 6.Irvine R. 2016. A tale of two inositol phosphates. Biochem. Soc. Trans. 44: 202–211. [DOI] [PubMed] [Google Scholar]
  • 7.Scherer J. 1850. Uber eine neue aus dem Muskelfleisch gewonnene Zuckerart. Liebigs Ann. Chem. 73: 322. [Google Scholar]
  • 8.Maquenne L. 1887. Préparation, proprietés et constitution se l’inosite. C.R. Hebd. Séance, Acad. Sci. Paris. 104: 225–227. [Google Scholar]
  • 9.Maquenne L. 1887. Sur les propriétés de l’inosite. C.R. Hebd. Séance, Acad. Sci. Paris. 104: 297–299. [Google Scholar]
  • 10.Maquenne L. 1887. Sur quelques dérivés de l’inosite. C.R. Hebd. Séance, Acad. Sci. Paris. 104: 1719–1722. [Google Scholar]
  • 11.Posternak T. 1942. Recherches dans la série des cyclites VI. Sut la configuration de la méso-inosite, de la scyllite et d’un inosose obtenu par voie biochimique (scyllo-ms-inosose). Helv. Chim. Acta. 25: 746–752. [Google Scholar]
  • 12.Dangschat G., and Fischer H. O. L.. 1942. Acetonierung und Konfiguration des Meso-inosits. Naturwissenschaften. 30: 146–147. [Google Scholar]
  • 13.Posternak T. 1965. Holden-Day, San Francisco. [Google Scholar]
  • 14.Posternak S. 1919. Sur la synthese de l’ether hexaphosphorique de l’inosite avec le principe phospho-organique de reserve des plantes vertes. Compt. Rend. Acad. Sci. 169: 138–140. [Google Scholar]
  • 15.Sherman W. R., Hipps P. P., Manck L. A., and Rasheed A.. 1978. Studies on enzymes of inositol metabolism. In Cyclitols and Phosphoinositides. W. W. Wells and F. Eisenberg, editors. Academic Press, New York. 279–295. [Google Scholar]
  • 16.Turner B. L., Paphazy M. J., Haygarth P. M., and McKelvie I. D.. 2002. Inositol phosphates in the environment. Philos. Trans. R. Soc. Lond. B Biol. Sci. 357: 449–469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Giles C. C., Cade-Menun B. J., and Hill J. E.. 2011. The inositol phosphates in soils and manures: abundance, cycling, and measurement. Can. J. Soil Sci. 91: 397–416. [Google Scholar]
  • 18.Turner B. L., Cheesman A. W., Godage H. Y., Riley A. M., and Potter B. V.. 2012. Determination of neo- and D-chiro-inositol hexakisphosphate in soils by solution 31P NMR spectroscopy. Environ. Sci. Technol. 46: 4994–5002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Martin J. B., Laussmann T., Bakker-Grunwald T., Vogel G., and Klein G.. 2000. Neo-inositol polyphosphates in the amoeba Entamoeba histolytica. J. Biol. Chem. 275: 10134–10140. [DOI] [PubMed] [Google Scholar]
  • 20.Anderson R. J. 1936. The chemistry of the lipoids of tubercule bacilli. XIV. The occurrence of inosite in the phosphatide of human tubercule bacilli. J. Am. Chem. Soc. 52: 1607–1608. [Google Scholar]
  • 21.Woolley D. W. 1943. Isolation and partial determination of structure of soybeasn lipositol, a new inositol-contaning phospholipid. J. Biol. Chem. 231: 813–828. [Google Scholar]
  • 22.Hawthorne J. N., and Chargaff E.. 1954. A study of inositol-containing lipides. J. Biol. Chem. 206: 27–37. [PubMed] [Google Scholar]
  • 23.McKibbin J. M. 1956. A monophosphoinositide of liver. J. Biol. Chem. 220: 537–545. [PubMed] [Google Scholar]
  • 24.Pizer F. L., and Ballou C. E.. 1959. Studies on myo-inositol phosphates of natural origin. J. Am. Chem. Soc. 81: 915–921. [Google Scholar]
  • 25.Ballou C. E., and Pizer F. L.. 1959. Synthesis of an optically active myoinositol 1-phosphate. J. Am. Chem. Soc. 81: 4745. [Google Scholar]
  • 26.Brown D. A., Clark B. F., and Letters R.. 1961. Phospholipids. Part VII. The structure of a monophosphoinositide. J. Chem. Soc. 3774–3779. [Google Scholar]
  • 27.Agranoff B. W. 1978. Cyclitol confusion. Trends Biochem. Sci. 3: N285. [Google Scholar]
  • 28.Irvine R. F., and Schell M. J.. 2001. Back in the water: the return of the inositol phosphates. Nat. Rev. Mol. Cell Biol. 2: 327–338. [DOI] [PubMed] [Google Scholar]
  • 29.Eisenberg F., Jr 1967. D-myoinositol 1-phosphate as the product of cyclization of glucose 6-phosphate and substrate for a specific phosphatase in rat testis. J. Biol. Chem. 242: 1375–1382. [PubMed] [Google Scholar]
  • 30.Folch J. 1942. Brain cephalin, a mixture of phoaphtides. Separation of it from phosphatidyl serine, phosphatidyl ethanolamine, and a fraction containing an inositol phosphatide. J. Biol. Chem. 146: 35–44. [Google Scholar]
  • 31.Folch J. 1949. Brain diphosphoinositide, a new phosphoinositide having inositol metadiphosphate as a constituent. J. Biol. Chem. 177: 505–519. [PubMed] [Google Scholar]
  • 32.Dittmer J. C., and Dawson R. M.. 1960. The isolation of a new complex lipid: triphosphoinositide from ox brain. Biochim. Biophys. Acta. 40: 379–380. [PubMed] [Google Scholar]
  • 33.Grado C., and Ballou C. E.. 1961. Myo-inositol phosphates obtained from alkaline hydrolysis of beef brain phosphoinositide. J. Biol. Chem. 236: 54–60. [PubMed] [Google Scholar]
  • 34.Tomlinson R. V., and Ballou C. E.. 1961. Complete characterisation of the myo-inositol polyphosphates from beef brain phosphoinositide. J. Biol. Chem. 236: 1902–1906. [PubMed] [Google Scholar]
  • 35.Brown D. M., and Stewart J. C.. 1966. The structure of triphosphoinositide from beef brain. Biochim. Biophys. Acta. 125: 413–421. [DOI] [PubMed] [Google Scholar]
  • 36.Balla T. 2013. Phosphoinositides: tiny lipids with giant impact on cell regulation. Physiol. Rev. 93: 1019–1137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Hokin M. R., and Hokin L. E.. 1953. Enzyme secretion and the incorporation of 32P into phospholipides of pancreas slices. J. Biol. Chem. 203: 967–977. [PubMed] [Google Scholar]
  • 38.Dawson R. M. C. 1954. The measurement of 32P labelling of individual kephalins and lecithin in a small sample of tissue. Biochim. Biophys. Acta. 14: 374–379. [DOI] [PubMed] [Google Scholar]
  • 39.Hokin L. E., and Hokin M. R.. 1955. Effects of acetylcholine on the turnover of phosphoryl units in individual phospholipids of pancreas slices and brain cortex slices. Biochim. Biophys. Acta. 18: 102–110. [DOI] [PubMed] [Google Scholar]
  • 40.Petzold G. L., and Agranoff B. W.. 1967. The biosynthesis of cytidine diphosphate diglyceride by embryonic chick brain. J. Biol. Chem. 242: 1187–1191. [PubMed] [Google Scholar]
  • 41.Hokin-Neaverson M. 1974. Acetylcholine causes a net decrease in phosphatidylinositol and a net increase in phosphatidic acid in mouse pancreas. Biochem. Biophys. Res. Commun. 58: 763–768. [DOI] [PubMed] [Google Scholar]
  • 42.Jones L. M., and Michell R. H.. 1974. Breakdown of phosphatidylinositol provoked by muscarinic cholinergic stimulation of rat parotid-gland fragments. Biochem. J. 142: 583–590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Abdel-Latif A. A., Akhtar R. A., and Hawthorne J. N.. 1977. Acetylcholine increases the breakdown of triphosphoinositide of rabbit iris muscle prelabelled with [32P] phosphate. Biochem. J. 162: 61–73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Dawson R. M. C. 1959. Studies on the enzymic hydrolysis of monophosphoinositide by phospholipase preparations from P. notatum and ox pancreas. Biochim. Biophys. Acta. 33: 68–77. [DOI] [PubMed] [Google Scholar]
  • 45.Kemp P., Hubscher G., and Hawthorne J. N.. 1961. Phosphoinositides. 3. Enzymic hydrolysis of inositol-containing phos­pholipids. Bio­chem. J. 79: 193–200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Hokin M. R., and Hokin L. E.. 1964. Interconversions of phosphatidylinositol and phosphatidic acid involved in the response to acetylcholine in the salt gland. In Metabolism and Physiological Significance of Lipids. R. M. C. Dawson and D. N. Rhodes, editors. John Wiley, London. 423–434. [Google Scholar]
  • 47.Michell R. H. 1975. Inositol phospholipids and cell surface receptor function. Biochim. Biophys. Acta. 415: 81–147. [DOI] [PubMed] [Google Scholar]
  • 48.Rhee S. G., and Choi K. D.. 1992. Regulation of phospholipid-specific phospholipase C isoforms. J. Biol. Chem. 267: 12393–12396. [PubMed] [Google Scholar]
  • 49.Durell J., and Garland J. T.. 1969. Acetylcholine-stimulated phosphodiesteratic cleavage of phosphoinositides: hypothetical role in membrane depolarization. Ann. N. Y. Acad. Sci. 165: 743–754. [PubMed] [Google Scholar]
  • 50.Cockcroft S. 1984. Ca2+-dependent conversion of phosphatidylinositol to phosphatidate in neutrophils stimulated with fMet-Leu-Phe or ionophore A23187. Biochim. Biophys. Acta. 795: 37–46. [DOI] [PubMed] [Google Scholar]
  • 51.Cockcroft S., and Allan D.. 1984. The fatty acid composition of phosphatidylinositol, phosphatidate and 1,2-diacylglycerol in stimulated human neutrophils. Biochem. J. 222: 557–559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Berridge M. J., and Fain J. N.. 1979. Inhibition of phosphatidylinositol synthesis and the inactivation of calcium entry after prolonged exposure of the blowfly salivary gland to 5-hydroxytryptamine. Biochem. J. 178: 59–69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Akhtar R. A., and Abdel-Latif A. A.. 1980. Requirement for calcium ions in acetylcholine-stimulated phosphodiesteratic cleavage of phosphatidyl-myo-inositol 4,5-bisphosphate in rabbit iris smooth muscle. Biochem. J. 192: 783–791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Low M. G., and Weglicki W. B.. 1983. Resolution of myocardial phospholipase C into several forms with distinct properties. Biochem. J. 215: 325–334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Irvine R. F., Letcher A. J., and Dawson R. M.. 1984. Phosphatidylinositol-4,5-bisphosphate phosphodiesterase and phosphomonoesterase activities of rat brain. Some properties and possible control mechanisms. Biochem. J. 218: 177–185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Wilson D. B., Bross T. E., Hofmann S. L., and Majerus P. W.. 1984. Hydrolysis of polyphosphoinositides by purified sheep seminal vesicle phospholipase C enzymes. J. Biol. Chem. 259: 11718–11724. [PubMed] [Google Scholar]
  • 57.Thompson W., and Dawson R. M. C.. 1964. The triphosphoinositide phosphodiesterase of brain tissue. Biochem. J. 91: 237–243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Dawson R. M., and Thompson W.. 1964. The triphosphoinositide phosphomonoesterase of brain tissue. Biochem. J. 91: 244–250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Rudge S. A., and Wakelam M. J.. 2016. Phosphatidylinositolphosphate phosphatase activities and cancer. J. Lipid Res. 57: 176–192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Berridge M. J. 1983. Rapid accumulation of inositol trisphosphate reveals that agonists hydrolyse polyphosphoinositides instead of phosphatidylinositol. Biochem. J. 212: 849–858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Berridge M. J., Buchan P. B., and Heslop J. P.. 1984. Relationship of polyphosphoinositide metabolism to the hormonal activation of the inset salivary gland by 5-hydroxytryptamine. Mol. Cell. Endocrinol. 36: 37–42. [DOI] [PubMed] [Google Scholar]
  • 62.Streb H., Irvine R. F., Berridge M. J., and Schulz I.. 1983. Release of Ca2+ from a nonmitochondrial intracellular store in pancreatic acinar cells by inositol-1,4,5-trisphosphate. Nature. 306: 67–69. [DOI] [PubMed] [Google Scholar]
  • 63.Mitchell J., Wang X., Zhang G., Gentzsch M., Nelson D. J., and Shears S. B.. 2008. An expanded biological repertoire for Ins(3,4,5,6)P4 through its modulation of ClC-3 function. Curr. Biol. 18: 1600–1605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Shears S. B. 2004. How versatile are inositol phosphate kinases? Biochem. J. 377: 265–280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Wilson M. S., Livermore T. M., and Saiardi A.. 2013. Inositol pyrophosphates: between signalling and metabolism. Biochem. J. 452: 369–379. [DOI] [PubMed] [Google Scholar]
  • 66.York J. D., Odom A. R., Murphy R., Ives E. B., and Wente S. R.. 1999. A phospholipase C-dependent inositol polyphosphate kinase pathway required for efficient messenger RNA export. Science. 285: 96–100. [DOI] [PubMed] [Google Scholar]
  • 67.Takai Y., Kishimoto A., Kikkawa U., Mori T., and Nishizuka Y.. 1979. Unsaturated diacylglycerol as a possible messenger for the activation of calcium-activated, phospholipid-dependent protein kinase system. Biochem. Biophys. Res. Commun. 91: 1218–1224. [DOI] [PubMed] [Google Scholar]
  • 68.Hammond G. R., Fischer M. J., Anderson K. E., Holdich J., Koteci A., Balla T., and Irvine R. F.. 2012. PI4P and PI(4,5)P2 are essential but independent lipid determinants of membrane identity. Science. 337: 727–730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Sugimoto Y., Whitman M., Cantley L. C., and Erikson R. L.. 1984. Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol. Proc. Natl. Acad. Sci. USA. 81: 2117–2121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Macara I. G., Marinetti G. V., and Balduzzi P. C.. 1984. Transforming protein of avian sarcoma virus UR2 is associated with phosphatidylinositol kinase activity: possible role in tumorigenesis. Proc. Natl. Acad. Sci. USA. 81: 2728–2732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Whitman M., Kaplan D., Roberts T., and Cantley L.. 1987. Evidence for two distinct phosphatidylinositol kinases in fibroblasts. Implications for cellular regulation. Biochem. J. 247: 165–174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Whitman M., Downes C. P., Keeler M., Keller T., and Cantley L.. 1988. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature. 332: 644–646. [DOI] [PubMed] [Google Scholar]
  • 73.Auger K. R., Serunian L. A., Soltoff S. P., Libby P., and Cantley L. C.. 1989. PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell. 57: 167–175. [DOI] [PubMed] [Google Scholar]
  • 74.Traynor-Kaplan A. E., Harris A. L., Thompson B. L., Taylor P., and Sklar L. A.. 1988. An inositol tetrakisphosphate-containing phospholipid in activated neutrophils. Nature. 334: 353–356. [DOI] [PubMed] [Google Scholar]
  • 75.Schu P. V., Takegawa K., Fry M. J., Stack J. H., Waterfield M. D., and Emr S. D.. 1993. Phosphatidylinositol 3-kinase encoded by yeast VPS34 gene essential for protein sorting. Science. 260: 88–91. [DOI] [PubMed] [Google Scholar]
  • 76.Stephens L., Cooke F. T., Walters R., Jackson T., Volinia S., Gout I., Waterfield M. D., and Hawkins P. T.. 1994. Characterization of a phosphatidylinositol-specific phosphoinositide 3-kinase from mammalian cells. Curr. Biol. 4: 203–214. [DOI] [PubMed] [Google Scholar]
  • 77.Stephens L. R., Hughes K. T., and Irvine R. F.. 1991. Pathway of phosphatidylinositol(3,4,5)-trisphosphate synthesis in activated neutrophils. Nature. 351: 33–39. [DOI] [PubMed] [Google Scholar]
  • 78.Hawkins P. T., Jackson T. R., and Stephens L. R.. 1992. Platelet-derived growth factor stimulates synthesis of PtdIns(3,4,5)P3 by activating a PtdIns(4,5)P2 3-OH kinase. Nature. 358: 157–159. [DOI] [PubMed] [Google Scholar]
  • 79.Toker A. 2012. Phosphoinositide 3-kinases - a historical perspective. Subcell. Biochem. 58: 95–110. [DOI] [PubMed] [Google Scholar]
  • 80.Morii H., Ogawa M., Fukuda K., Taniguchi H., and Koga Y.. 2010. A revised biosynthetic pathway for phosphatidylinositol in Mycobacteria. J. Biochem. 148: 593–602. [DOI] [PubMed] [Google Scholar]
  • 81.Koga Y. 2011. Early evolution of membrane lipids: how did the lipid divide occur? J. Mol. Evol. 72: 274–282. [DOI] [PubMed] [Google Scholar]
  • 82.Whiteford C. C., Brearley C. A., and Ulug E. T.. 1997. Phosphatidylinositol 3,5-bisphosphate defines a novel PI 3-kinase pathway in resting mouse fibroblasts. Biochem. J. 323: 597–601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Dove S. K., Cooke F. T., Douglas M. R., Sayers L. G., Parker P. J., and Michell R. H.. 1997. Osmotic stress activates phosphatidylinositol-3,5-bisphosphate synthesis. Nature. 390: 187–192. [DOI] [PubMed] [Google Scholar]
  • 84.Rameh L. E., Tolias K. F., Duckworth B. C., and Cantley L. C.. 1997. A new pathway for synthesis of phosphatidylinositol-4,5-bisphosphate. Nature. 390: 192–196. [DOI] [PubMed] [Google Scholar]
  • 85.Viaud J., Boal F., Tronchere H., Gaits-Iacovoni F., and Payrastre B.. 2014. Phosphatidylinositol 5-phosphate: a nuclear stress lipid and a tuner of membranes and cytoskeleton dynamics. BioEssays. 36: 260–272. [DOI] [PubMed] [Google Scholar]
  • 86.Bulley S. J., Clarke J. H., Droubi A., Giudici M. L., and Irvine R. F.. 2015. Exploring phosphatidylinositol 5-phosphate 4-kinase function. Adv. Biol. Regul. 57: 193–202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Fiume R., Stijf-Bultsma Y., Shah Z. H., Keune W. J., Jones D. R., Jude J. G., and Divecha N.. 2015. PIP4K and the role of nuclear phosphoinositides in tumour suppression. Biochim. Biophys. Acta. 1851: 898–910. [DOI] [PubMed] [Google Scholar]
  • 88.Cocco L., Gilmour R. S., Ognibene A., Letcher A. J., Manzoli F. A., and Irvine R. F.. 1987. Synthesis of polyphosphoinositides in nuclei of Friend cells. Evidence for polyphosphoinositide metabolism inside the nucleus which changes with cell differentiation. Biochem. J. 248: 765–770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Divecha N., Banfic H., and Irvine R. F.. 1991. The polyphosphoinositide cycle exists in the nuclei of Swiss 3T3 cells under the control of a receptor (for IGF-I) in the plasma membrane, and stimulation of the cycle increases nuclear diacylglycerol and apparently induces translocation of protein kinase C to the nucleus. EMBO J. 10: 3207–3214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Gonzales M. L., and Anderson R. A.. 2006. Nuclear phosphoinositide kinases and inositol phospholipids. J. Cell. Biochem. 97: 252–260. [DOI] [PubMed] [Google Scholar]
  • 91.Low M. G., and Finean J. B.. 1978. Specific release of plasma membrane enzymes by a phosphatidylinositol-specific phospholipase C. Biochim. Biophys. Acta. 508: 565–570. [DOI] [PubMed] [Google Scholar]
  • 92.Low M. G., and Zilversmit D. B.. 1980. Role of phosphatidylinositol in attachment of alkaline phosphatase to membranes. Biochemistry. 19: 3913–3918. [DOI] [PubMed] [Google Scholar]
  • 93.Low M. G., and Kincade P. W.. 1985. Phosphatidylinositol is the membrane-anchoring domain of the Thy-1 glycoprotein. Nature. 318: 62–64. [DOI] [PubMed] [Google Scholar]
  • 94.Ferguson M. A., Low M. G., and Cross G. A.. 1985. Glycosyl-sn-1,2-dimyristylphosphatidylinositol is covalently linked to Trypanosoma brucei variant surface glycoprotein. J. Biol. Chem. 260: 14547–14555. [PubMed] [Google Scholar]
  • 95.Ferguson M. A. 1997. The surface glycoconjugates of trypanosomatid parasites. Philos. Trans. R. Soc. Lond. B Biol. Sci. 352: 1295–1302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Dawson R. M. C. 1966. The metabolism of animal phospholipids, and their turnover in animal cells. In Essays in Biochemistry. P. N. Campbell and G. D. Greville, editors. Academic Press, London & New York. 69–115. [Google Scholar]
  • 97.Irvine R. 1997. First steps into the signalling maze. Curr. Biol. 7: R457. [DOI] [PubMed] [Google Scholar]
  • 98.Irvine R. F. 2003. Timeline: 20 years of Ins(1,4,5)P3, and 40 years before. Nat. Rev. Mol. Cell Biol. 4: 580–585. [DOI] [PubMed] [Google Scholar]
  • 99.Hinchliffe K. A., Ciruela A., and Irvine R. F.. 1998. PIPkins, their substrates and their products: new functions for old enzymes. Biochim. Biophys. Acta. 1436: 87–104. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Lipid Research are provided here courtesy of American Society for Biochemistry and Molecular Biology

RESOURCES